KBC Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

KBC Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,096	Closed	-$540K	–	1837
2025 Q1	$540K	Buy	4,096 +322	+9%	+$40.1K	﹤0.01%	712
2024 Q4	$315K	Buy	3,774 +910	+32%	+$74.8K	﹤0.01%	925
2024 Q3	$210K	Buy	2,864 +423	+17%	+$31.8K	﹤0.01%	904
2024 Q2	$167K	Buy	2,441 +355	+17%	+$24.6K	﹤0.01%	926
2024 Q1	$144K	Buy	2,086 +308	+17%	+$21.2K	﹤0.01%	965
2023 Q4	$127K	Hold	1,778	–	–	﹤0.01%	965
2023 Q3	$93K	Buy	+1,778	New	+$104K	﹤0.01%	1044

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

KBC Group's ITCI Position: Q2 2025 in Review

KBC Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 4,096 shares — an estimated $540K sold.

KBC Group first reported a position in ITCI in Q3 2023 and held it in 7 quarters. The position peaked at $540K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

KBC Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
KBC Group sold 4,096 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $540K.
KBC Group first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 7 quarters.
KBC Group's Intra-Cellular Therapies Inc. position peaked at $540K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on KBC Group's 13F filing for Q2 2025, filed 8 Aug 2025.